A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Sponsor: MedImmune LLC
Terminated
Early termination of the study due to lack of efficacy.
Other terminated trials from MedImmune LLC
- TNBC - Triple-Negative Breast Cancer · Phase PHASE1 · May 2023
- Healthy Volunteers · Phase PHASE1 · May 2020
- Colorectal Neoplasms · Phase PHASE1 · Oct 2018
- CTCL · Phase PHASE1 · Oct 2018
- Respiratory Syncytial Virus · Phase PHASE2 · Nov 2016
More terminations from MedImmune LLC
Other Idiopathic Pulmonary Fibrosis trials with similar outcome
A PHASE2 clinical study on Idiopathic Pulmonary Fibrosis, this trial is terminated or withdrawn. The trial is conducted by MedImmune LLC and has accumulated 9 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MedImmune LLC
For direct contact, visit the study record on ClinicalTrials.gov .